The Japanese pharma has been building a presence in oncology over the last few years through products such as its Adcetris (brentuximab vedotin), and its $5.2 billion acquisition of Ariad at the ...
The Japanese pharma company acquired Ariad a year ago for $5.2bn, and the latest, more modest acquisition, shows that Takeda's chief Christophe Weber sees buy-outs as ongoing route to growth.
The FDA accepted applications for a golimumab biosimilar, while Samsung Biologics reported record sales, and a Japanese ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback